医学
彭布罗利珠单抗
肾细胞癌
免疫疗法
佐剂
全身疗法
肿瘤科
内科学
辅助治疗
癌
肾癌
化疗
癌症
乳腺癌
作者
Talal El Zarif,Karl Semaan,Wanling Xie,Marc Eid,Martín Zarbá,Wadih Issa,Tian Zhang,Charles B. Nguyen,Ajjai Alva,Catherine C. Fahey,Kathryn E. Beckermann,José A. Karam,Matthew T. Campbell,Giuseppe Procopio,Marco Stellato,Sebastiano Buti,Anežka Zemánková,Bohuslav Melichar,Francesco Massari,Veronica Mollica
标识
DOI：10.1016/j.eururo.2024.07.016
摘要
Adjuvant pembrolizumab significantly improved overall survival (OS) in renal cell carcinoma (RCC), but real-world data on sequential treatment are scarce. We sought to evaluate the clinical outcomes of first-line (1L) systemic therapy following adjuvant immune oncology (IO)-based regimens.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cdercder
剑指东方是为谁
bc
平常的毛豆
Luminous
飞快的泥猴桃
jyy
LaTeXer
故酒
MchemG
昏睡的蟠桃
Li
就叫柠檬吧
Russula_Chu
Billy
余味
繁荣的心情
wuludie
WaitP
斯寜
皖公网安备34019202002308
